These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8044802)

  • 1. 3-Methylcholanthrene inactivates the p53 gene in Syrian hamster embryo fibroblasts by inducing a specific intronic point mutation.
    Albor A; Flessate DM; Soussi T; Notario V
    Cancer Res; 1994 Aug; 54(16):4502-7. PubMed ID: 8044802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient transcription of the human angiotensin II type 2 receptor gene requires intronic sequence elements.
    Warnecke C; Willich T; Holzmeister J; Bottari SP; Fleck E; Regitz-Zagrosek V
    Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):17-24. PubMed ID: 10229654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
    Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
    Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular cloning and functional analysis of the promoter region of rat nonmuscle myosin heavy chain-B gene.
    Yam JW; Chan KW; Li N; Hsiao WL
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1203-9. PubMed ID: 11027611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines.
    Yaginuma Y; Westphal H
    Cancer Res; 1992 Aug; 52(15):4196-9. PubMed ID: 1638534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
    Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
    Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
    Cote RJ; Jhanwar SC; Novick S; Pellicer A
    Cancer Res; 1991 Oct; 51(19):5410-6. PubMed ID: 1913660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-specific expression, evolutionary conservation and localization of the cph proto-oncogene on Syrian hamster chromosome X.
    Velasco JA; Zimonjic DB; Popescu NC; Cansado J; DiPaolo JA; Albor A; Notario V
    Oncogene; 1996 Jun; 12(12):2713-7. PubMed ID: 8700531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
    Takimoto R; El-Deiry WS
    Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a p53-dependent negative response element in the bcl-2 gene.
    Miyashita T; Harigai M; Hanada M; Reed JC
    Cancer Res; 1994 Jun; 54(12):3131-5. PubMed ID: 8205530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onchocerca volvulus superoxide dismutase genes: identification of functional promoters for pre-mRNA transcripts which undergo trans-splicing.
    Tawe W; Walter RD; Henkle-Dührsen K
    Exp Parasitol; 2000 Mar; 94(3):172-9. PubMed ID: 10831382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
    Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
    Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell lines: identification of a specific 30 bp fragment in the proximal promoter region.
    Ge YW; Ghosh C; Song W; Maloney B; Lahiri DK
    J Neurochem; 2004 Sep; 90(6):1432-44. PubMed ID: 15341527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutations in spontaneously immortalized 3T12 but not 3T3 mouse embryo cells.
    Rittling SR; Denhardt DT
    Oncogene; 1992 May; 7(5):935-42. PubMed ID: 1349164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
    Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
    Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The properties of p53 proteins selected for the loss of suppression of transformation.
    Olson DC; Levine AJ
    Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning and initial analysis of the human multidrug resistance-related MVP/LRP gene promoter.
    Lange C; Walther W; Schwabe H; Stein U
    Biochem Biophys Res Commun; 2000 Nov; 278(1):125-33. PubMed ID: 11071864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interaction of p53 with p53 response element like binding sequence at upstream of hepatitis B virus enhancer I].
    Qu JH; Zhu MH; Lin J; Ni CR; Li FM; Zhu Z; Yu GZ
    Ai Zheng; 2004 May; 23(5):502-7. PubMed ID: 15142443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations.
    Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y
    Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.